Xie Jian-Jiang, Zhuo Yang-Jia, Zheng Yu, Mo Ru-Jun, Liu Ze-Zhen, Li Bo-Wei, Cai Zhi-Duan, Zhu Xue-Jin, Liang Yu-Xiang, He Hui-Chan, Zhong Wei-de
Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
Int Urol Nephrol. 2017 May;49(5):817-823. doi: 10.1007/s11255-017-1545-7. Epub 2017 Feb 17.
Abnormal spindle microtubule assembly (ASPM) gene was known to be linked with poor clinical prognosis in various tumors. However, the clinical significance of ASPM in prostate cancer (PCa) has not yet been understood. The purpose of this study was to determine the association of ASPM with tumor progression and prognosis in PCa patients.
The expression of ASPM at protein level in human PCa and non-cancerous prostate tissue was detected by immunohistochemical analysis, which was further validated by using microarray-based dataset (NCBI GEO: GSE21032 and The Cancer Genome Atlas (TCGA) dataset) at mRNA level. Subsequently, the association of ASPM expression with the clinicopathological characteristics of patients with PCa was then statistically analyzed.
Immunohistochemistry and dataset analyses revealed that ASPM expression was significantly increased in the PCa tissues with high Gleason score. Additionally, as showed by two datasets, ASPM expression was significantly high expressed in the PCa tissues when compared with the non-cancerous tissues, especially in advanced PCa pathological stage. The upregulation of ASPM mRNA expression in the PCa tissues significantly correlated with the presence of tumor metastasis, shorter overall survival and prostate-specific antigen (PSA) failure. Furthermore, both univariate and multivariate analyses showed that the upregulation of ASPM was a potential predictor of poor biochemical recurrence (BCR)-free survival.
Our data suggest that ASPM may play an important role in the progression of PCa. More importantly, the increased expression of ASPM may potentially predict poor BCR-free survival in patients with PCa.
已知异常纺锤体微管组装（ASPM）基因与多种肿瘤的不良临床预后相关。然而，ASPM在前列腺癌（PCa）中的临床意义尚未明确。本研究的目的是确定ASPM与PCa患者肿瘤进展及预后的关系。
通过免疫组织化学分析检测人PCa组织和非癌前列腺组织中ASPM蛋白水平的表达，并使用基于微阵列的数据集（NCBI GEO：GSE21032和癌症基因组图谱（TCGA）数据集）在mRNA水平上进一步验证。随后，对ASPM表达与PCa患者临床病理特征的关系进行统计学分析。
免疫组织化学和数据集分析显示，在高Gleason评分的PCa组织中，ASPM表达显著增加。此外，两个数据集均显示，与非癌组织相比，PCa组织中ASPM表达显著上调，尤其是在晚期PCa病理阶段。PCa组织中ASPM mRNA表达的上调与肿瘤转移的存在、较短的总生存期和前列腺特异性抗原（PSA）失败显著相关。此外，单因素和多因素分析均显示，ASPM的上调是生化复发（BCR）无进展生存期不良的潜在预测指标。
我们的数据表明，ASPM可能在PCa进展中起重要作用。更重要的是，ASPM表达的增加可能预示PCa患者BCR无进展生存期较差。
